Busulfan

Pharmacogenomic Information in the Context of the FDA-Approved Drug Label*

Excerpt from the busulfan drug label:

"Busulfan is clearly less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome. Also, the so-called "juvenile" type of chronic myelogenous leukemia, typically occurring in young children and associated with the absence of a Philadelphia chromosome, responds poorly to busulfan."

(For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Busulfan drug label PDF.)

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.